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Sofosbuvir and Ribavirin Therapy for 
Children Aged 3 to <12 Years With 
Hepatitis C Virus Genotype 2 or 3 
Infection
Philip Rosenthal,1 Kathleen B. Schwarz,2 Regino P. Gonzalez-Peralta,3 Chuan-Hao Lin,4 Deidre A. Kelly,5 Scott Nightingale,6 
William F. Balistreri,7 Sanjay Bansal,8 Maureen M. Jonas,9 Benedetta Massetto,10 Diana M. Brainard,10 Chia-Hsiang Hsueh,10  
Jiang Shao,10 Bandita Parhy,10 Suzanne Davison,11 Cornelia Feiterna-Sperling,12 Lynette A. Gillis,13 Giuseppe Indolfi,14  
Etienne M. Sokal ,15 Karen F. Murray,16 and Stefan Wirth17
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon 
plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks 
in children aged 3 to <12 years chronically infected with genotype 2 or for 24 weeks in patients with genotype 3. 
Patients aged 3 to <6 years weighing <17 kg received sofosbuvir 150 mg, and patients aged 3 to <6 years weigh-
ing ≥17 kg and all patients aged 6 to <12 years received sofosbuvir 200 mg once daily. Intensive pharmacokinetic 
sampling conducted in each age group confirmed the appropriateness of sofosbuvir doses. For all patients, ribavirin 
dosing was determined by baseline weight (up to 1,400 mg/day, two divided doses). The primary efficacy endpoint 
was sustained virologic response 12 weeks after therapy (SVR12). Fifty-four patients were enrolled (41 aged 6 to 
<12 years and 13 aged 3 to <6 years). Most were treatment naïve (98%) and infected perinatally (94%). All but one 
patient achieved SVR12 (53/54, 98%; 95% confidence interval, 90%-100%). The patient who did not achieve SVR12 
was a 4-year-old who discontinued treatment after 3 days because of “abnormal drug taste.” The most commonly 
reported adverse events in patients aged 6 to <12 years were vomiting (32%) and headache (29%), and those in 
patients aged 3 to <6 years were vomiting (46%) and diarrhea (39%). One 3-year-old patient had a serious adverse 
event of accidental ribavirin overdose requiring hospitalization for monitoring; this patient completed treatment and 
achieved SVR12. Conclusion: Sofosbuvir plus ribavirin was well tolerated and highly effective in children aged 3 to 
<12 years with chronic HCV genotype 2 or 3 infection. (Hepatology 2020;71:31-43).
Worldwide, it is estimated that 2.1 to 5 million children under 15 years of age have chronic hepatitis C virus (HCV) 
infection.(1,2) In children, chronic HCV infection is 
often asymptomatic or with mild, nonspecific symp-
toms. However, progression to significant fibrosis can 
occur,(3) and cases of cirrhosis,(4-6) hepatocellular car-
cinoma,(7,8) and end-stage liver disease requiring liver 
Abbreviations: AUC, area under the curve; BMI, body mass index; CI, confidence interval; GT, genotype; HCV, hepatitis C virus; INR, 
international normalized ratio of prothrombin time; NI, nucleotide inhibitor; NS5B, nonstructural protein 5B; PK, pharmacokinetic; RAS, 
resistance-associated substitution; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response.
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transplantation(9,10) have been reported. In addition, 
quality of life and cognitive function may be compro-
mised in children with HCV.(10-12)
In children, the primary route of HCV infection 
is through perinatal transmission, with an approx-
imate transmission rate from an HCV-infected 
mother of 5%.(13) In the presence of inadequately 
controlled human immunodeficiency virus (HIV) 
coinfection or high HCV RNA viral loads (>6 log 
IU/mL) in the mother, transmission rates are as high 
as 14%.(14) The increasing intravenous opioid use 
by women of child-bearing age in some countries 
such as the United States raises concern about 
a possible increase in the number of newborns 
infected with HCV.(15) Furthermore, the prevalence 
rate may be underestimated as a result of the lack 
of universal screening in pregnant women or in 
newborns.(16)
In 2017, sofosbuvir and ledipasvir-sofosbuvir were 
approved to treat HCV in adolescents aged 12 to <18 
years and, in certain countries, in younger pediatric 
patients weighing at least 35 kg.(17-20) However, for 
children younger than 12 years of age (or in cer-
tain countries <35 kg), the only approved treatment 
remains pegylated interferon plus ribavirin admin-
istered for 24 weeks for genotype (GT)2 and GT3 
or 48 weeks for GT1. Treatment with pegylated 
interferon plus ribavirin is undesirable because of 
safety concerns, poor tolerability, and its parenteral 
route of administration.(21) Concern for the effects 
of pegylated interferon and ribavirin on growth and 
development in this age group also limits their use.(22) 
As such, current international guidelines recommend 
that in patients younger than 12 years of age, treat-
ment should be deferred until direct-acting antivirals 
are available.(2,23-25)
We evaluated the safety and efficacy of sofos-
buvir, a potent oral HCV nonstructural protein 5B 
(NS5B) polymerase inhibitor, in combination with 
weight-based ribavirin, in children aged 3 to <6 
years and 6 to <12 years with HCV GT2 or GT3 
chronic infection.
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Eligible patients were 3 to <12 years of age and 
had chronic infection with HCV G2 or G3, with 
plasma HCV RNA levels ≥1,000 IU/mL at screen-
ing. Patients could be either HCV treatment naïve 
or experienced. Patients with or without cirrho-
sis were eligible; liver biopsy was not required for 
study entry. Patients were required to have an abso-
lute neutrophil count ≥1,500/mm3 and a hemoglo-
bin level of ≥11 g/dL for females and ≥12 g/dL for 
males. Patients were excluded from participating 
in the study if they had any of the following con-
ditions: decompensated liver disease; chronic liver 
disease of a non-HCV etiology; alfa-fetoprotein 
level >50 ng/mL; serum creatinine >1.5 mg/dL; esti-
mated glomerular filtration rate <90 mL/minute/ 
1.73 m2 as calculated by the Schwartz Formula; evi-
dence of hepatocellular carcinoma or other malig-
nancy; infection with hepatitis A, hepatitis B, or 
HIV; significant cardiovascular, pulmonary, or 
neurological disease; evidence of a gastrointestinal 
malabsorption syndrome that could interfere with 
absorption of orally administered medications; his-
tory of solid organ or bone marrow transplantation; 
chronic daily nonsteroidal anti-inflammatory drug 
therapy; systemic corticosteroid use for ≥5 days 
(pulmonary/nasal administration was permitted); 
psychiatric hospitalization, suicide attempt, or dis-
ability resulting from psychiatric illness. Parents or 
legal guardians provided written informed consent 
before patients undertook any study-related proce-
dures. Patients who could read and write provided 
written assent.
StUDy DeSIgN
This was a phase 2, multicenter, open-label study. 
Based on the approved indication for sofosbuvir in 
adult patients, treatment was administered for 12 
weeks in patients with HCV GT2 and 24 weeks in 
those with HCV GT3. Sofosbuvir was administered 
once daily. Patients aged 6 to <12 years received 
200 mg sofosbuvir as either two 100-mg tablets or 
four 50-mg capsules containing granules, as deter-
mined by a swallowability assessment completed at 
screening or treatment day 1. Patients aged 3 to <6 
years weighing ≥17 kg received sofosbuvir 200 mg 
in four 50-mg capsules containing granules, and 
those weighing <17 kg received sofosbuvir 150 mg 
in three 50-mg capsules containing granules. Tablets 
were administered with or without food. Granules 
were to be removed from the capsules and were 
administered orally with or without food. If taken 
with food, the granules were to be sprinkled on a 
spoonful of nonacidic soft food at room tempera-
ture or cooler, such as pudding or ice cream, and 
then swallowed without chewing. If taken without 
food, the granules were to be taken first and then 
washed down with liquid, and not mixed into the 
liquid. These requirements were meant to preserve 
the taste-mask coating over the bitter taste of sofos-
buvir during administration. Ribavirin dosing was 
twice daily, based on weight (Table 1), and was to 
be taken with food.
At least 10 patients 6 to <12 years of age under-
went an intensive pharmacokinetic (PK) evaluation 
(PK lead-in phase) on day 7 of dosing in order to 
confirm the appropriateness of the sofosbuvir dose 
selected (200 mg). Based on the intensive PK data in 
the patients aged 6 to <12 years, the sofosbuvir doses 
tested in the younger patients aged 3 to <6 years were 
selected (200 mg  ≥  17 kg and 150 mg for <17 kg). 
Similarly, at least 10 patients aged 3 to <6 years were 
to be enrolled into a PK lead-in phase, with intensive 
PK evaluation on day 7. Patients of both age groups 
enrolled in the PK lead-in phase had to be naïve to 
HCV treatment and have no documented cirrhosis. In 
taBle 1. Ribavirin Dosing and administration
Body Weight (kg)
Ribavirin Daily 
Dose No. of Capsules*
<47 15 mg/kg/day Oral solution. Divided dose in 
morning and evening
47-49 600 mg/day 1 × 200-mg capsules am
2 × 200-mg capsules pm
50-65 800 mg/day 2 × 200-mg capsules am
2 × 200-mg capsules pm
66-80 1,000 mg/day 2 × 200-mg capsules am
3 × 200-mg capsules pm
81-105 1,200 mg/day 3 × 200-mg capsules am
3 × 200-mg capsules pm
>105 1,400 mg/day 3 × 200-mg capsules am
4 × 200-mg capsules pm
*For patients of any weight who were unable or unwilling to take 
ribavirin capsules, oral solution could be used at 15 mg/kg/day 
divided morning and evening.
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addition, patients in the 6 to <12-year-old group were 
to weigh ≥17 kg and <45 kg, whereas there was no 
weight limit for patients in the 3 to <6-year-old group. 
Patients enrolled in the PK lead-in phases contin-
ued treatment without interruption, while additional 
patients of each age group were enrolled on confirma-
tion that the selected doses were appropriate. There 
were no weight limits for the additional patients of 
either age group enrolled in the study.
Study visits occurred at screening, treatment day 1, 
and weeks 1, 2, 4, 8, 12, (and as applicable) 16, 20, 
and 24. All patients were to complete follow-up visits 
at posttreatment weeks 4, 12, and 24. Instead of the 
week 1 study visit, patients in the pharmacokinetic 
lead-in phase attended two study visits of day 3 and 
day 7.
The study protocol was approved by the review 
board or ethics committee of each institution before 
study initiation. The study (ClinicalTrials.gov 
Identifier: NCT02175758; EudraCT Number: 2014-
002283-32) was conducted in accordance with the 
International Conference on Harmonization Good 




Screening assessments included measurement of 
the serum HCV RNA level, and the HCV genotype 
and subtype. HCV RNA levels were quantified by 
using the Ampliprep/COBAS TaqMan HCV Test, 
v2.0 (Roche Molecular Systems, Inc., Branchburg, 
NJ), which has a lower limit of quantification (LLOQ) 
of 15 IU/mL. HCV genotype and subtype were 
determined using the Siemens VERSANT HCV 
Genotype INNO-LiPA2.0 Assay. Plasma HCV RNA 
levels were evaluated on treatment day 1; at treatment 
weeks 1, 2, 4, 8, and 12 for all patients and at weeks 
16, 20, and 24 for patients receiving 24 weeks of treat-
ment; and at posttreatment weeks 4, 12, and 24.
Resistance
Plasma samples for viral sequencing were col-
lected at all visits during treatment and follow-up, 
following the same schedule as for HCV RNA 
evaluation. Sequencing of the HCV NS5B regions 
was attempted for all enrolled patients at base-
line and with virologic failure, if applicable. The 
HCV NS5B coding region was amplified by DDL 
Diagnostic Laboratory (Rijswijk, the Netherlands) 
using standard reverse-transcription polymerase 
chain reaction technology. Following amplifica-
tion, polymerase chain reaction products were deep 
sequenced, and resistance-associated substitutions 
(RASs) that were present in more than 15% of 
the sequence reads were reported. NS5B nucleo-
side inhibitor RASs were defined as follows: S96T, 
N142T, L159F, E237G, S282any, M/F289L/I, 
L320F/I/V, and V321A/I.
Safety
Complete physical examinations were conducted 
at screening, on day 1 of treatment, and at the final 
treatment visit. At the screening and all treatment 
visits, data regarding vital signs, reported adverse 
events, concomitant medication intake, and clini-
cal laboratory tests were collected. At all follow-up 
visits, symptom-directed physical exams were done, 
and vital signs and reported adverse events were 
collected. Concomitant medications were reported 
at the follow-up week 4 visit, and clinical labora-
tory tests were done at the follow-up weeks 4 and 
12 visits.
Swallowability and palatability
For patients aged 6 to <12 years, swallowability of 
the tablet formulation was assessed at screening or day 
1 using a placebo-to-match tablet. Any patient unable 
to swallow the tablet received the granule formulation. 
For any patients aged 6 to <12 years dosed with gran-
ules and all patients aged 3 to <6 years receiving the 
granule formulation, palatability was assessed on day 
1 after the first dose of study drug. Patients reported 
whether they were able to taste the formulation (yes 
or no).
growth and Development
All patients underwent a Tanner pubertal stage 
assessment at baseline and follow-up week 12 vis-
its.(26,27) Z scores were calculated for height, weight, 
and body mass index (BMI) assessed at baseline and 
at follow-up week 12.
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pharmacokinetics
For the first patients (at least 10) in each age group, an 
intensive PK lead-in evaluation was performed to con-
firm the appropriateness of the sofosbuvir doses selected 
for each age group. At the day 7 visit, serial blood sam-
ples were collected to determine the pharmacokinetics 
of sofosbuvir and its primary metabolite, GS-331007. 
Blood samples were collected at time 0 (≤30 minutes 
before dosing), after which patients were provided a stan-
dardized meal. Within 5 minutes after consuming the 
meal, patients were dosed with study drug. For patients 
aged 6 to <12 years, blood samples were collected at 0.5, 
1, 2, 3, 4, 8, and 12 hours after dosing; food intake for 
this age group was restricted until after the collection 
of the 4-hour postdose sample. For patients aged 3 to 
<6 years, blood samples were collected at 2, 4, 8, and 12 
hours after dosing with no food intake restrictions. For 
the PK analysis, the predose (0 minute) concentration 
results also served as 24-hour postdose concentrations.
eNDpoINtS
The primary efficacy endpoint was the percentage 
of patients who achieved sustained virologic response 
12 weeks after discontinuing study drugs (SVR12), 
defined as having HCV RNA < LLOQ (15 IU/mL). 
The primary safety endpoint was any adverse event 
leading to permanent discontinuation of study drug(s).
StatIStICal aNalySeS
Efficacy, safety, and pharmacokinetics were 
assessed in all patients who received at least one dose 
of study drug. The SVR12 rate was calculated with 
a 2-sided 95% exact confidence interval (CI) based 
on the Clopper-Pearson method. Missing SVR val-
ues were imputed as a success if bracketed by values 
that were termed successes. Clinical and laboratory 
adverse events were summarized using the Medical 
Dictionary for Regulatory Activities, version 20.1. 
Z scores were calculated for height and weight 
changes over time. An age- and sex-specific z score 
was derived for each weight, height, and BMI mea-
surement according to the downloadable SAS pro-
gram available on the Centers for Disease Control 
and Prevention (CDC) web site using the year 2000 
growth charts. CDC methods and the SAS program 
were applied to calculate the z score.(28,29)
The pharmacokinetic parameters of study drug 
were estimated by noncompartmental analysis using 
WinNonlin V7 (Certara USA, Inc., Princeton, NJ). 
Results were summarized descriptively. Appropriateness 
of the dose was confirmed by comparing GS-331007 
area under the curve (AUC)tau from each age group with 
the integrated adult data from phase 2 and 3 clinical 
studies. The 90% CIs were constructed for the ratio of 
geometric means of pharmacokinetic parameters men-
tioned above. The equivalence boundary was set as 50% 
to 200% of the adult data. Exploratory analyses using 
the same approach were conducted for GS-331007 
Cmax, sofosbuvir AUCtau, and sofosbuvir Cmax.
Results
patIeNt popUlatIoN
From July 17, 2015, to September 13, 2018, 63 
patients were screened, and 54 patients (41 aged 6 to 
<12 years and 13 aged 3 to <6 years) were enrolled 
and treated at 28 sites in Australia, Belgium, Germany, 
Italy, New Zealand, the United Kingdom, and the 
United States. The 9 patients not enrolled did not 
meet eligibility criteria.
Among 41 patients aged 6 to <12 years, 13 had 
GT2 HCV infection and 28 had GT3 HCV infec-
tion  (Table 2). The median age was 9 (range, 6-11) 
years, 98% (40/41) were infected through perinatal 
transmission, and all but one were treatment naïve. 
The single patient who was treatment experienced 
was an 8-year-old who had prior partial response to 
pegylated interferon plus ribavirin. Seventy-three per-
cent of patients were female, and 71% were white. 
None of the patients had documented cirrhosis. Of 
the 41 patients who initiated treatment, all completed 
treatment (Fig. 1).
Among 13 patients aged 3 to <6 years, 5 had 
GT2 HCV infection and 8 had GT3 HCV infection 
(Table 2). The median age was 4 (range, 3-5) years, 
85% (11/13) were infected through perinatal trans-
mission, and all were treatment naïve. Seventy-seven 
percent of patients were female, and 69% were white. 
Eight patients (62%) weighed less than 17 kg at base-
line. None of the patients had documented cirrhosis. Of 
the 13 patients who initiated treatment, 12 completed 
treatment (Fig. 1). One patient discontinued treatment 
after 3 days because of “abnormal drug taste.”
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VIRologIC ReSpoNSe
Among patients aged 6 to <12 years, all (100%; 
95% CI, 91%-100%) achieved SVR12 (13/13 [95% 
CI, 75%-100%] with GT2 and 28/28 [95% CI, 
88%-100%] with GT3; Table 3). Among patients 
aged 3 to <6 years, 12/13 (92%; 95% CI, 64%-100%) 
achieved SVR12 (4/5 [80%; 95% CI, 28%-100%] 
with GT2 and 8/8 [95% CI, 63%-100%] with GT3). 
No patients had virologic nonresponse or relapse after 
treatment. The GT2 patient who did not achieve 
SVR12 was a 4-year-old who discontinued treatment 
after 3 days because of an adverse event of “abnormal 
drug taste.”
SaFety
Overall, treatment was generally safe and well 
tolerated. In both age groups, all adverse events were 
mild or moderate in intensity. Among patients aged 
6 to <12 years, the most commonly reported adverse 
events were vomiting (32%) and headache (29%; 
Table 4). Among the patients aged 3 to <6 years, the 
most common adverse events were vomiting (46%) 
and diarrhea (39%). All adverse events of diarrhea 
lasted ≤5 days and resolved while treatment was 
ongoing, with the exception of one case that lasted for 
2 months, beginning during treatment and resolving 
during the posttreatment period. All adverse events 
of vomiting lasted for 1 or 2 days, and the major-
ity resolved without changes to drug dosing, with 
the exception of 1 patient in the 6 to <12-year-old 
group and 2 patients in the 3 to <6-year-old group 
for whom treatment was interrupted for 1 day. Two 
of these three patients were able to complete treat-
ment. One 4-year-old patient with a medical history 
of fetal alcohol syndrome had an adverse event of 
vomiting of both the sofosbuvir granules and rib-
avirin oral solution on day 1, and study drug was 
interrupted for 1 day; dosing was again attempted 
on day 3 when the patient experienced an adverse 
event of product use issue (reported term, “spitting 
up dose”) for both sofosbuvir granules and ribavirin 
oral solution and an adverse event of “product taste 
abnormal” (reported term, “bad taste”) for sofosbuvir 
granules that resulted in permanent study drug dis-
continuation. This is the only patient across the two 
age groups that did not complete treatment because 
of an adverse event. According to the investigator, 
the sofosbuvir granules were administered with 
applesauce and yogurt on day 1, both of which are 
acidic and may have broken down the taste-mask 
coating of the granules.
taBle 2. patient Demographics and Baseline 
Characteristics
Characteristics
3 to <6 Years  
(n = 13)
6 to <12 Years  
(n = 41)
Age (years) 4 (3-5) 9 (6-11)
Female sex 10 (77) 30 (73)
Race
White 9 (69) 29 (71)
Asian 1 (8) 8 (20)
Black 1 (8) 0
Other 2 (15) 4 (10)
Weight (kg) 17 (13, 19) 30 (15, 80)
Weight <17 kg, n (%) 8 (62) 1 (2)
Median weight for age 
percentile (IQR)
51.9 (35.8) 51.7 (63.8)
Height (cm) 102 (97-113) 131 (109-160)
BMI (kg/m2) 15 (13-17) 17 (13-32)
Median BMI for age percen-
tile (IQR)
52.1 (28.9) 60.2 (50.1)
HCV genotype
2 5 (39) 13 (32)
2a/2c 0 4 (10)
2b 4 (31) 7 (17)
No confirmed subtype 1 (8) 2 (5)
3 8 (62) 28 (68)
3a 8 (62) 28 (68)
HCV RNA (log10 IU/mL) 5.4 (4.4-7.2) 5.8 (2.2-7.8)
HCV RNA ≥800,000 IU/mL 3 (23) 19 (46)
HCV treatment history
Treatment naïve 13 (100) 40 (98)




No 2 (15) 5 (12)
Unknown 11 (85) 36 (88)
ALT (U/L) 25 (11-76) 34 (14-583)
eGFR (mL/min/1.73 m2)* 151 (99-232) 158 (79-241)
Mode of HCV infection
Perinatal transmission 11 (85) 40 (98)
Unknown 2 (15) 1 (2)
Note: Data are presented as n (%) or median (range) unless oth-
erwise indicated.
*Estimated using the Schwartz Formula.
Abbreviations: ALT, alanine aminotransferase; eGFR, estimated 
glomerular filtration rate; PEG, peginterferon.
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Across both age groups, only 1 patient experienced 
a serious adverse event. One 3-year-old patient had a 
serious adverse event of accidental overdose of ribavi-
rin by ingestion on day 83, which required hospital-
ization for monitoring, and which led to interruption 
of sofosbuvir and ribavirin from day 83 to day 92. 
The patient remained asymptomatic. Sofosbuvir was 
restarted on day 92; ribavirin was initially restarted at 
a lower dose on day 92, and the full dose was rein-
troduced on day 102 when the event was considered 
resolved.
Only 1 patient had a grade 3 laboratory abnormal-
ity of increased international normalized ratio of pro-
thrombin time (INR). This occurred in a 10-year-old 
patient with a baseline level of INR 1.1 who experi-
enced grade 3 increases of INR level at week 2 (3.2), 
week 4 (3.6), and week 20 (3.0), followed by normal-
ization at the last visit on treatment. The same blood 
samples were also tested at a local laboratory and the 
abnormal INR results were not confirmed. According 
to the investigator, this patient had normal liver tests 
and these abnormal INR results were potentially due 
to testing error. This laboratory abnormality was not 
reported as an adverse event and was not associated 
with any adverse events. One 6-year-old female patient 
had a postbaseline hemoglobin level of 9.9 g/dL 
at week 4, which increased to 11.4 g/dL by week 8 
and remained at a normal level for the remainder 
of the study, without requiring ribavirin dose inter-
ruption or modification. No grade 3 or 4 laboratory 
abnormalities were observed in the 3 to <6-year-old 
group.
Ribavirin treatment was interrupted for 1 patient 
in the 6 to <12-year-old group for 1 day because 
of vomiting. For 2 patients in the 3 to <6-year-old 
group, ribavirin was interrupted for one because of 
vomiting during attempted dosing and for the other 
because of an accidental overdose of ribavirin as 
described above. One 3-year-old patient discontin-
ued ribavirin along with sofosbuvir on treatment day 
FIg. 1. Patient disposition.
63 Screened
9 did not meet eligibility criteria 
and were not enrolled
54 Enrolled
1 discontinued 
treatment early due 
to adverse events
18 assessed for efficacy and 
safety
36 assessed for efficacy and 
safety
17 completed treatment
18 with HCV Genotype 2 
Received Sofosbuvir + Ribavirin 
for 12 weeks
36 with HCV Genotype 3
Received Sofosbuvir + Ribavirin 
for 24 weeks
36 completed treatment
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3 as described above because of the adverse event 
of spitting up and “abnormal drug taste.” With the 
exception of 1 patient with an isolated postbaseline 
hemoglobin level of 9.9 g/dL described above, no 
patient experienced clinically significant hemoglo-
bin reductions or changes in lymphocyte, reticulo-
cyte, platelet, or neutrophil counts typically observed 
in patients treated with ribavirin.
palataBIlIty aND 
SWalloWaBIlIty
Among the 41 patients aged 6 to <12 years, 40 were 
assessed for swallowability of the 100-mg tablet formu-
lation, whereas 1 patient inadvertently performed the 
swallowability assessment with a sofosbuvir 400-mg 
placebo tablet instead of the 100-mg tablet. This 
patient was able to swallow the 400-mg placebo tablet 
and was administered sofosbuvir 100-mg tablets. Of 
the 40 patients assessed with the 100-mg placebo tab-
let, 34 (85%) were able to swallow it successfully. The 
remaining 6 patients (15%) were administered sofos-
buvir as granules. In addition, 1 patient who was able 
to swallow the placebo tablet was instead administered 
the granule formulation because of an adverse event of 
“abnormal product taste” reported after administration 
of the tablet formulation on day 1. Of the 7 patients 
who were administered oral granules, 3 (43%) were 
able to taste the granules; all 3 completed treatment.
In patients aged 3 to <6 years, 12 of 13 patients 
were administered oral granules, and 9 (75%) 
reported being able to taste the study medication. 
Among these 9 patients, 8 (89%) completed treat-
ment. One patient performed the swallowability test 
for the sofosbuvir 100-mg tablet and was adminis-
tered this formulation in spite of being <6 years of 
age.
gRoWtH aND DeVelopMeNt
As assessed by Tanner pubertal staging, study 
treatment did not affect pubertal development 
through 12 weeks of posttreatment follow-up. At 
baseline, 34 of 41 patients aged 6 to <12 years were 
at Tanner stage 1 for pubic hair and genitalia or 
breast development. At posttreatment week 12, all 
taBle 3. treatment Response to Sofosbuvir and Ribavirin
3 to <6 Years 6 to <12 Years
SOF 200 mg or  
150 mg + RBV  
12 Weeks
SOF 200 mg or  
150 mg + RBV  
24 Weeks
SOF 200 mg + 
RBV  
12 Weeks
SOF 200 mg + 
RBV  
24 Weeks
HCV GT2 (n = 5) HCV GT3 (n = 8) Total (n = 13) HCV GT2 (n = 13) HCV GT3 (n = 28) Total (n = 41)
HCV RNA < 15 IU/mL, n/n (%)
On treatment
Week 1 2/4 (50) 3/8 (38) 5/12 (42) 6/13 (46) 11/28 (39) 17/41 (41)
Week 2 3/4 (75) 7/8 (88) 10/12 (83) 10/13 (77) 22/28 (79) 32/41 (78)
Week 4 3/4 (75) 8/8 (100) 11/12 (92) 13/13 (100) 27/28 (96) 40/41 (98)
Week 8 4/4 (100) 8/8 (100) 12/12 (100) 13/13 (100) 27/28 (96) 40/41 (98)
Week 12 4/4 (100) 8/8 (100) 12/12 (100) 13/13 (100) 28/28 (100) 41/41 (100)
After treatment
Week 4 4/5 (80) 8/8 (100) 12/13 (92) 13/13 (100) 28/28 (100) 41/41 (100)
Week 12 (SVR12) 4/5 (80) 8/8 (100) 12/13 (92) 13/13 (100) 28/28 (100) 41/41 (100)
95% CI 28%-100% 63%-100% 64%-100% 75%-100% 88%-100% 91%-100%
Virologic failure, n (%)
On treatment 0 0 0 0 0 0
Relapse 0 0 0 0 0 0
Early treatment  
discontinuation, n (%)
1 (20) 0 1 (8) 0 0 0
Abbreviation: NA, not applicable.
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40 patients with available data had no change or an 
increase from baseline Tanner staging. For patients 
aged 3 to <6 years, 11 of 11 with available Tanner 
staging were at Tanner stage 1 for pubic hair and 
genitalia or breast development at both baseline and 
at posttreatment week 12.
Median changes in z scores for height, weight, and 
BMI were calculated in each age group by treatment 
from baseline to end of treatment (12 weeks for GT2 
and 24 weeks for GT3), and from end of treatment 
to posttreatment week 12 (Table 5). For patients aged 
6 to <12 years, the median changes from baseline to 
end of treatment among all measures ranged between 
−0.07 and −0.02, and from end of treatment to post-
treatment week 12 between −0.01 and 0.05. For 
patients aged 3 to <6 years, the median changes from 
baseline to end of treatment ranged between −0.41 
and −0.01 among all measures, and median changes 
from end of treatment to posttreatment week 12 
ranged between −0.16 and 0.32.
taBle 4. adverse events and laboratory abnormalities
3 to <6 Years 6 to <12 Years
SOF 200 mg or  
150 mg + RBV  
12 Weeks
SOF 200 mg or 
150 mg + RBV  
24 Weeks
SOF 200 mg + 
RBV  
12 Weeks
SOF 200 mg + 
RBV  
24 Weeks
HCV GT2 (n = 5) HCV GT3 (n = 8) Total (n = 13) HCV GT2 (n = 13) HCV GT3 (n = 28) Total (n = 41)
No. (%) of patients with any 
adverse event
5 (100) 8 (100) 13 (100) 9 (69) 26 (93) 35 (85)
No. of grade 3 or 4 adverse 
events
0 0 0 0 0 0
No. (%) of patients with a 
serious adverse event
0 1 (13) 1 (8) 0 0 0
No. (%) of patients with 
adverse events leading to 
discontinuation
1 (20) 0 1 (8) 0 0 0
Adverse events leading to 
discontinuation, n
Product use issue 1 (20) 0 1 (8) 0 0 0
Product taste abnormal 1 (20) 0 1 (8) 0 0 0
Adverse events in ≥10% of 
patients of either age 
group, n (%)
Vomiting 3 (60) 3 (38) 6 (46) 2 (15) 11 (39) 13 (32)
Headache 0 0 0 4 (31) 8 (29) 12 (29)
Fatigue 1 (20) 1 (13) 2 (15) 3 (23) 5 (18) 8 (20)
Diarrhea 2 (40) 3 (38) 5 (38) 1 (8) 3 (11) 4 (10)
Cough 1 (20) 0 1 (8) 1 (8) 7 (25) 8 (20)
Decreased appetite 0 3 (38) 3 (23) 2 (15) 2 (7) 4 (10)
Nasopharyngitis 0 0 0 1 (8) 4 (14) 5 (12)
Nausea 0 1 (13) 1 (8) 0 4 (14) 4 (10)
Oropharyngeal pain 0 1 (13) 1 (8) 0 4 (14) 4 (10)
Rhinorrhea 0 1 (13) 1 (8) 1 (8) 3 (11) 4 (10)
Pyrexia 1 (20) 0 1 (8) 0 4 (14) 4 (10)
Serious adverse events
Accidental overdose 0 1 (13) 1 (8) 0 0 0
Laboratory abnormalities
INR, Grade 3 (>2.0 to 3.0 × 
ULN)
0 0 0 0 1 (4) 1 (2)
Deaths 0 0 0 0 0 0
Abbreviation: ULN, upper limit of normal.
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pHaRMaCoKINetICS
The 12 patients aged 6 to <12 years and the 11 
patients aged 3 to <6 years who underwent intensive 
PK sampling had similar demographics to the overall 
study populations. During dosing, 2 patients aged 6 to 
<12 years were overdosed and 1 aged 3 to <6 years was 
dosed with a tablet instead of granules; these patients 
were excluded from the intensive PK analysis. The 
plasma exposures of sofosbuvir and GS-331007 in the 
20 patients from both age groups receiving the age/
weight-based doses of 150 mg or 200 mg of sofosbuvir 
were comparable to those observed in adults receiving 
400 mg of sofosbuvir in clinical trials. The 90% CIs for 
GS-331007 AUCtau in patients from both age groups 
were within the predefined PK equivalence boundaries 
of 50% to 200% when compared with adults from the 
phase 2 and 3 studies (Table 6). These data supported 
the appropriateness of doses evaluated in the study.
ReSIStaNCe aNalySeS
Baseline deep sequencing of the NS5B nucleotide 
inhibitor (NI) region was performed on all 41 patients 
aged 6 to <12 years and was obtained for 40 of 41 
patients. Full-length NS5B amplification was unsuc-
cessful for 1 patient with GT3; a short fragment was 
obtained for this patient. At baseline, the NS5B NI 
RAS M289I was detected in 2 of 41 patients, both of 
whom had GT2b. Both achieved SVR12.
Deep sequencing was performed on all 12 patients 
aged 3 to <6 years who completed treatment, and 
sequences were obtained for 11 of 12 patients. NS5B 
amplification was unsuccessful for 1 patient with 
GT3a infection because of assay failure. No baseline 
NS5B NI RASs were detected in any patients.
Discussion
Sofosbuvir plus ribavirin is approved for treatment 
of chronic HCV infection in adolescents 12 years and 
older and, in certain countries, in younger patients 
weighing at least 35 kg; however, pegylated inter-
feron plus ribavirin continues to be the only approved 
treatment for younger children.(17-20) Therefore, the 
availability of an all-oral, interferon-free, direct- 
acting antiviral regimen for younger children remains 
an unmet medical need. To our knowledge, this is 
largest study of sofosbuvir plus ribavirin in children 
younger than 12 years of age, and as young as 3 years 
old. Previously, 24 treatment-naïve patients aged 5 to 
12 years who received sofosbuvir plus ribavirin for 24 
weeks achieved SVR in a study by Hashmi et al. (data 
not reported).(30)
In our study, sofosbuvir plus ribavirin for 12 or 24 
weeks was highly effective in treating children 3 to 
<12 years of age with chronic hepatitis C infection 
genotypes 2 or 3, with 100% of patients aged 6 to 
taBle 5. Median z Score Changes in Height, Weight, and BMI
3 to <6 Years 6 to <12 Years
SOF 200 mg or 150 mg + RBV  
12 Weeks
SOF 200 mg or 150 mg + RBV 
24 Weeks
SOF 200 mg + RBV  
12 Weeks
SOF 200 mg + RBV  
24 Weeks
HCV GT2 (n = 5) HCV GT3 (n = 8) HCV GT2 (n = 13) HCV GT3 (n = 28)
z score change in height
Baseline to EOT −0.02 (−0.17 to 0.02) −0.01 (−0.48 to 0.13) −0.06 (−0.41 to 0.06) −0.10 (−0.36 to 0.24)
EOT to PTw12 −0.16 (−0.33 to 0.31) 0.01 (−0.34 to 0.11) 0.02 (−0.21 to 0.33) 0.05 (−0.19 to 0.38)
z score change in weight
Baseline to EOT −0.05 (−0.25 to 0.00) −0.41 (−0.69 to 0.35) −0.04 (−0.36 to 1.39) −0.18 (−0.53 to 0.36)
EOT to PTw12 −0.03 (−0.11 to 0.29) 0.09 (−0.21 to 0.22) 0.05 (−0.35 to 0.29) 0.04 (−0.30 to 0.40)
z score change in BMI
Baseline to EOT −0.12 (−0.25 to 0.24) −0.38 (−1.19 to 0.47) −0.02 (–0.46 to 2.70) −0.19 (−0.57 to 0.65)
EOT to PTw12 0.32 (−0.40 to 0.49) 0.13 (−0.35 to 0.71) 0.02 (−0.39 to 0.45) −0.01 (−0.48 to 0.34)
Note: Data are presented as median (range).
Abbreviations: EOT, end of treatment; PTw12, post-treatment week 12.
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<12 years and 92% of patients aged 3 to <6 years 
achieving SVR12. No patient experienced virologic 
failure. The only patient who did not reach SVR12 
was 4 years old and discontinued treatment after 3 
days because of the adverse event of spitting up and 
“abnormal drug taste” related to study drug. These 
results are similar to prior observations in adoles-
cents 12 to <18 years of age in which sofosbuvir plus 
ribavirin was highly efficacious and well tolerated 
in this younger population.(31) Despite the well- 
described hematologic toxicity of ribavirin, only 1 
patient in this study (1/54, 2%) experienced a tran-
sient reduction in hemoglobin to below 10 g/dL. 
This reduction resolved while still on treatment 
without changing or interrupting ribavirin dosing. 
In addition, no patient interrupted or modified rib-
avirin dosing because of an adverse event of low 
hemoglobin. In the study by Murray et al., 2 pedi-
atric patients aged 6 to 11 years with GT3 infection 
who received ledipasvir-sofosbuvir plus ribavirin 
similarly did not experience hematologic laboratory 
abnormalities despite treatment with ribavirin.(32)
Most patients aged 6 to <12 years were able to 
swallow the 100-mg tablet, and all completed treat-
ment. Additionally, although 3 of 7 patients receiving 
the oral granule formulation reported being able to 
taste the medication, all but 1 completed treatment. 
According to the investigator, this patient was admin-
istered the oral granules with acidic foods, which 
should be avoided in order to preserve the taste-mask 
coating. This highlights the importance of adminis-
tering granules with appropriate nonacidic and soft 
foods in order to ensure successful dosing in young 
children.
The SVR12 rates in this study for both age groups 
(patients 6 to <12 years of age, 100% in both GT2 
and GT3, and in patients 3 to <6 years of age, 80% in 
GT2 and 100% in GT3(31)) were comparable to the 
SVR12 rates observed with sofosbuvir plus ribavirin 
in adolescents 12 to <18 years of age (100% [13/13] 
in GT2 and 97% [38/39] in GT3) as well as response 
rates in treatment-naïve adults (97% for GT2(33,34) 
and 94% in GT3(34)).
In summary, the safety and efficacy of treatment 
with sofosbuvir plus ribavirin observed in this study 
supports its use in children. Treating HCV infec-
tion in pediatric patients could limit both horizon-
tal and perinatal transmission of the virus, which 
could be important in reaching the World Health 
Organization’s goal of eliminating chronic HCV 
infection as a major public health threat by 2030.(35)
Limitations of this study include a relatively small 
sample size, and only patients with GT2 or GT3 were 
enrolled. The decision to enroll only GT2 or GT3 
pediatric patients follows the approved indications 
for adults, as only patients with GT2 or GT3 are 
approved for sofosbuvir plus ribavirin treatment. For 
adult patients with GT1 or GT4, sofosbuvir treatment 
is administered with ribavirin and peginterferon alfa. 
Because of the undesirable safety effects of peginter-
feron, we elected not to evaluate sofosbuvir plus rib-
avirin and peginterferon in GT1 or GT4 pediatric 
patients. Additionally, only 1 patient had prior treat-
ment experience and no patients had known cirrhosis; 
therefore, we were unable to evaluate whether these 
factors affect response to sofosbuvir and ribavirin in 
children 3 to <12 years of age. Although the ideal 
treatment for pediatric patients would not include 
taBle 6. Mean (% CV) Sofosbuvir and gS-331007 exposures
Adults  
(n = 1,695)
3 to <6 Years  
(n = 10)
3 to <6 Years vs. Adults 
% GMR (90% CI)
6 to <12 Years  
(n = 10)
6 to <12 years vs. Adults 
% GMR (90% CI)
Sofosbuvir*
AUCtau (ng•hour/mL) 1,030 (36.5) 1,690
† NA 960 (45.1) 89.8 (75.0-108)
Cmax (ng/mL) 511 (32.5) 681
† NA 609 (43.4) 114 (92.4-140)
GS-331007
AUCtau (ng•hour/mL) 7,120 (30.7) 10,300 (18.1) 150 (127-176) 7,650 (22.5) 110 (93.3-129)
Cmax (ng/mL) 582 (36.3) 1,320 (20.0) 239 (195-292) 905 (25.6) 161 (132-198)
Note: Data are presented to 3 significant digits.
*n = 838 for sofosbuvir in adults.
†n = 1 for sofosbuvir in patients aged 3 to <6 years as 9 patients could not be evaluated by noncompartmental analysis.
Abbreviations: CV, coefficient of variation; GMR, geometric mean ratio; NA, not applicable.
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ribavirin, sofosbuvir plus ribavirin was well tolerated 
in this study, with no patient discontinuing ribavi-
rin because of low hemoglobin levels. In addition, 
although the follow-up period was short, we did not 
observe an impact on development and growth, which 
are issues that have previously been reported with the 
use of pegylated interferon plus ribavirin.(22) Clinical 
trials with ribavirin-free, pangenotypic regimens such 
as sofosbuvir-velpatasvir (ClinicalTrials.gov identi-
fier: NCT03022981) and glecaprevir-pibrentasvir 
(NCT03067129) in the age groups studied here are 
ongoing.
In conclusion, sofosbuvir and ribavirin was well tol-
erated and highly effective in treating children aged 3 
to <12 years with chronic HCV GT2 or GT3 infec-
tion. As such, sofosbuvir in combination with ribavi-
rin would provide an important strategy for treating 
chronic HCV infection in the pediatric population as 
well as improving public health.
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